Icu Medical Stock Price, News & Analysis

ICU Medical, Inc. (Nasdaq:ICUI) reported fourth quarter 2021 revenue of $340.5 million, up from $320.5 million the previous year. GAAP gross profit rose to $127.5 million with a stable gross margin of 37%. The company posted a GAAP net income of $19.9 million ($0.91 per diluted share), down from $26.1 million ($1.21 per diluted share) year-over-year. Adjusted diluted EPS improved to $1.82 from $1.77. Looking ahead, ICU Medical expects adjusted EBITDA for fiscal 2022 between $450 million and $500 million, with adjusted diluted EPS ranging from $9.00 to $10.50.

ICU Medical (Nasdaq:ICUI) announced the schedule for its fourth quarter 2021 earnings release and conference call. The company will publish its results on February 24, 2022, at approximately 4:00 p.m. ET. A conference call will follow at 4:30 p.m. ET, accessible at (855) 327-6837 with conference ID 10017891. The call will also be available via webcast on the company's website. ICU Medical specializes in infusion systems and critical care products and is headquartered in San Clemente, California.

ICU Medical (NASDAQ: ICUI) has successfully acquired Smiths Medical from Smiths Group (LSE: SMIN.L), enhancing its position in the infusion therapy market. The combined revenue is projected at approximately $2.5 billion. This acquisition aims to create a scalable US-based competitor, improving supply chain stability and allowing for growth aligned with evolving clinical care models. ICU Medical plans to announce its complete FY 2022 guidance during its Q4 earnings call in late February.

ICU Medical (Nasdaq: ICUI) will present at the J.P. Morgan 40^th Annual Healthcare Conference, scheduled from January 10-13, 2022. The presentation is set for January 12, 2022, at 10:30 a.m. PST (1:30 p.m. EST). Investors can access the live webcast on the company's website under the Investors tab. ICU Medical focuses on innovative products for infusion therapy and critical care, including IV smart pumps and closed system transfer devices. More details are available at www.icumed.com.

ICU Medical (Nasdaq:ICUI) reported a revenue increase of $336.1 million for the third quarter of 2021, up from $318.6 million in Q3 2020. The GAAP net income rose to $31.1 million, or $1.43 per diluted share, compared to $25.0 million, or $1.16 per diluted share, in the same quarter last year. Adjusted diluted EPS also increased to $2.07 from $1.90. The GAAP gross profit was $127.8 million with a gross margin of 38%. Notably, infusion consumables saw a significant increase, while IV solutions experienced a decline.

ICU Medical (Nasdaq:ICUI) announced its third quarter 2021 earnings release will occur on November 3, 2021, at approximately 4:00 p.m. ET. A conference call will follow at 4:30 p.m. ET, accessible via phone at (877) 407-3982 or through a webcast on the company's website. ICU Medical specializes in infusion therapy and critical care products, including IV smart pumps and safety software. The webcast will also be available for replay.

ICU Medical has announced its commitment to acquire Smiths Medical, expanding its infusion therapy capabilities with estimated combined revenues of $2.5 billion. The deal includes 2.5 million newly issued shares valued at $500 million and $1.85 billion in cash, alongside certain liabilities. Smiths will hold a 10% stake in ICU Medical post-transaction, with a board seat contingent on stock ownership. The acquisition is subject to regulatory approvals and is anticipated to close in H1 2022, strengthening ICU Medical's market position and enhancing customer service.

ICU Medical has announced a voluntary recall of one lot (2,112 units) of Aminosyn II, 15% due to visible particulate matter. This recall, effective nationwide, was initiated after fibers and proteinaceous material were detected in retain samples during routine inspections. The recalled product could pose health risks, including inflammation or severe blood clots. To date, no adverse events have been reported. The product is intended for nutritional support in patients unable to tolerate oral intake. Customers are advised to cease use and return the product.

ICU Medical reported second quarter 2021 revenue of $321.7 million, up from $303.4 million a year earlier. Gross profit rose to $123.5 million, with a gross margin of 38%, compared to 35% in Q2 2020. Net income was $28.4 million or $1.31 per diluted share, increasing from $18.9 million or $0.88 per share in the prior year. The company updated its 2021 guidance, adjusting expected adjusted EBITDA to $250 million to $260 million and adjusted diluted EPS to $6.80 to $7.20.